Cargando…

Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study

BACKGROUND: In individuals suffering from a rare disease the diagnostic process and the confirmation of a final diagnosis often extends over many years. Factors contributing to delayed diagnosis include health care professionals' limited knowledge of rare diseases and frequent (co-)occurrence o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hebestreit, Helge, Zeidler, Cornelia, Schippers, Christopher, de Zwaan, Martina, Deckert, Jürgen, Heuschmann, Peter, Krauth, Christian, Bullinger, Monika, Berger, Alexandra, Berneburg, Mark, Brandstetter, Lilly, Deibele, Anna, Dieris-Hirche, Jan, Graessner, Holm, Gündel, Harald, Herpertz, Stephan, Heuft, Gereon, Lapstich, Anne-Marie, Lücke, Thomas, Maisch, Tim, Mundlos, Christine, Petermann-Meyer, Andrea, Müller, Susanne, Ott, Stephan, Pfister, Lisa, Quitmann, Julia, Romanos, Marcel, Rutsch, Frank, Schaubert, Kristina, Schubert, Katharina, Schulz, Jörg B., Schweiger, Susann, Tüscher, Oliver, Ungethüm, Kathrin, Wagner, Thomas O. F., Haas, Kirsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842899/
https://www.ncbi.nlm.nih.gov/pubmed/35164804
http://dx.doi.org/10.1186/s13023-022-02176-1
_version_ 1784651141655560192
author Hebestreit, Helge
Zeidler, Cornelia
Schippers, Christopher
de Zwaan, Martina
Deckert, Jürgen
Heuschmann, Peter
Krauth, Christian
Bullinger, Monika
Berger, Alexandra
Berneburg, Mark
Brandstetter, Lilly
Deibele, Anna
Dieris-Hirche, Jan
Graessner, Holm
Gündel, Harald
Herpertz, Stephan
Heuft, Gereon
Lapstich, Anne-Marie
Lücke, Thomas
Maisch, Tim
Mundlos, Christine
Petermann-Meyer, Andrea
Müller, Susanne
Ott, Stephan
Pfister, Lisa
Quitmann, Julia
Romanos, Marcel
Rutsch, Frank
Schaubert, Kristina
Schubert, Katharina
Schulz, Jörg B.
Schweiger, Susann
Tüscher, Oliver
Ungethüm, Kathrin
Wagner, Thomas O. F.
Haas, Kirsten
author_facet Hebestreit, Helge
Zeidler, Cornelia
Schippers, Christopher
de Zwaan, Martina
Deckert, Jürgen
Heuschmann, Peter
Krauth, Christian
Bullinger, Monika
Berger, Alexandra
Berneburg, Mark
Brandstetter, Lilly
Deibele, Anna
Dieris-Hirche, Jan
Graessner, Holm
Gündel, Harald
Herpertz, Stephan
Heuft, Gereon
Lapstich, Anne-Marie
Lücke, Thomas
Maisch, Tim
Mundlos, Christine
Petermann-Meyer, Andrea
Müller, Susanne
Ott, Stephan
Pfister, Lisa
Quitmann, Julia
Romanos, Marcel
Rutsch, Frank
Schaubert, Kristina
Schubert, Katharina
Schulz, Jörg B.
Schweiger, Susann
Tüscher, Oliver
Ungethüm, Kathrin
Wagner, Thomas O. F.
Haas, Kirsten
author_sort Hebestreit, Helge
collection PubMed
description BACKGROUND: In individuals suffering from a rare disease the diagnostic process and the confirmation of a final diagnosis often extends over many years. Factors contributing to delayed diagnosis include health care professionals' limited knowledge of rare diseases and frequent (co-)occurrence of mental disorders that may complicate and delay the diagnostic process. The ZSE-DUO study aims to assess the benefits of a combination of a physician focusing on somatic aspects with a mental health expert working side by side as a tandem in the diagnostic process. STUDY DESIGN: This multi-center, prospective controlled study has a two-phase cohort design. METHODS: Two cohorts of 682 patients each are sequentially recruited from 11 university-based German Centers for Rare Diseases (CRD): the standard care cohort (control, somatic expertise only) and the innovative care cohort (experimental, combined somatic and mental health expertise). Individuals aged 12 years and older presenting with symptoms and signs which are not explained by current diagnoses will be included. Data will be collected prior to the first visit to the CRD’s outpatient clinic (T0), at the first visit (T1) and 12 months thereafter (T2). OUTCOMES: Primary outcome is the percentage of patients with one or more confirmed diagnoses covering the symptomatic spectrum presented. Sample size is calculated to detect a 10 percent increase from 30% in standard care to 40% in the innovative dual expert cohort. Secondary outcomes are (a) time to diagnosis/diagnoses explaining the symptomatology; (b) proportion of patients successfully referred from CRD to standard care; (c) costs of diagnosis including incremental cost effectiveness ratios; (d) predictive value of screening instruments administered at T0 to identify patients with mental disorders; (e) patients’ quality of life and evaluation of care; and f) physicians’ satisfaction with the innovative care approach. CONCLUSIONS: This is the first multi-center study to investigate the effects of a mental health specialist working in tandem with a somatic expert physician in CRDs. If this innovative approach proves successful, it will be made available on a larger scale nationally and promoted internationally. In the best case, ZSE-DUO can significantly shorten the time to diagnosis for a suspected rare disease. Trial registration ClinicalTrials.gov; Identifier: NCT03563677; First posted: June 20, 2018, https://clinicaltrials.gov/ct2/show/NCT03563677.
format Online
Article
Text
id pubmed-8842899
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88428992022-02-16 Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study Hebestreit, Helge Zeidler, Cornelia Schippers, Christopher de Zwaan, Martina Deckert, Jürgen Heuschmann, Peter Krauth, Christian Bullinger, Monika Berger, Alexandra Berneburg, Mark Brandstetter, Lilly Deibele, Anna Dieris-Hirche, Jan Graessner, Holm Gündel, Harald Herpertz, Stephan Heuft, Gereon Lapstich, Anne-Marie Lücke, Thomas Maisch, Tim Mundlos, Christine Petermann-Meyer, Andrea Müller, Susanne Ott, Stephan Pfister, Lisa Quitmann, Julia Romanos, Marcel Rutsch, Frank Schaubert, Kristina Schubert, Katharina Schulz, Jörg B. Schweiger, Susann Tüscher, Oliver Ungethüm, Kathrin Wagner, Thomas O. F. Haas, Kirsten Orphanet J Rare Dis Research BACKGROUND: In individuals suffering from a rare disease the diagnostic process and the confirmation of a final diagnosis often extends over many years. Factors contributing to delayed diagnosis include health care professionals' limited knowledge of rare diseases and frequent (co-)occurrence of mental disorders that may complicate and delay the diagnostic process. The ZSE-DUO study aims to assess the benefits of a combination of a physician focusing on somatic aspects with a mental health expert working side by side as a tandem in the diagnostic process. STUDY DESIGN: This multi-center, prospective controlled study has a two-phase cohort design. METHODS: Two cohorts of 682 patients each are sequentially recruited from 11 university-based German Centers for Rare Diseases (CRD): the standard care cohort (control, somatic expertise only) and the innovative care cohort (experimental, combined somatic and mental health expertise). Individuals aged 12 years and older presenting with symptoms and signs which are not explained by current diagnoses will be included. Data will be collected prior to the first visit to the CRD’s outpatient clinic (T0), at the first visit (T1) and 12 months thereafter (T2). OUTCOMES: Primary outcome is the percentage of patients with one or more confirmed diagnoses covering the symptomatic spectrum presented. Sample size is calculated to detect a 10 percent increase from 30% in standard care to 40% in the innovative dual expert cohort. Secondary outcomes are (a) time to diagnosis/diagnoses explaining the symptomatology; (b) proportion of patients successfully referred from CRD to standard care; (c) costs of diagnosis including incremental cost effectiveness ratios; (d) predictive value of screening instruments administered at T0 to identify patients with mental disorders; (e) patients’ quality of life and evaluation of care; and f) physicians’ satisfaction with the innovative care approach. CONCLUSIONS: This is the first multi-center study to investigate the effects of a mental health specialist working in tandem with a somatic expert physician in CRDs. If this innovative approach proves successful, it will be made available on a larger scale nationally and promoted internationally. In the best case, ZSE-DUO can significantly shorten the time to diagnosis for a suspected rare disease. Trial registration ClinicalTrials.gov; Identifier: NCT03563677; First posted: June 20, 2018, https://clinicaltrials.gov/ct2/show/NCT03563677. BioMed Central 2022-02-14 /pmc/articles/PMC8842899/ /pubmed/35164804 http://dx.doi.org/10.1186/s13023-022-02176-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hebestreit, Helge
Zeidler, Cornelia
Schippers, Christopher
de Zwaan, Martina
Deckert, Jürgen
Heuschmann, Peter
Krauth, Christian
Bullinger, Monika
Berger, Alexandra
Berneburg, Mark
Brandstetter, Lilly
Deibele, Anna
Dieris-Hirche, Jan
Graessner, Holm
Gündel, Harald
Herpertz, Stephan
Heuft, Gereon
Lapstich, Anne-Marie
Lücke, Thomas
Maisch, Tim
Mundlos, Christine
Petermann-Meyer, Andrea
Müller, Susanne
Ott, Stephan
Pfister, Lisa
Quitmann, Julia
Romanos, Marcel
Rutsch, Frank
Schaubert, Kristina
Schubert, Katharina
Schulz, Jörg B.
Schweiger, Susann
Tüscher, Oliver
Ungethüm, Kathrin
Wagner, Thomas O. F.
Haas, Kirsten
Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study
title Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study
title_full Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study
title_fullStr Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study
title_full_unstemmed Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study
title_short Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study
title_sort dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (zse-duo): study protocol for a controlled multi-center cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842899/
https://www.ncbi.nlm.nih.gov/pubmed/35164804
http://dx.doi.org/10.1186/s13023-022-02176-1
work_keys_str_mv AT hebestreithelge dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT zeidlercornelia dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT schipperschristopher dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT dezwaanmartina dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT deckertjurgen dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT heuschmannpeter dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT krauthchristian dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT bullingermonika dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT bergeralexandra dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT berneburgmark dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT brandstetterlilly dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT deibeleanna dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT dierishirchejan dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT graessnerholm dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT gundelharald dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT herpertzstephan dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT heuftgereon dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT lapstichannemarie dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT luckethomas dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT maischtim dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT mundloschristine dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT petermannmeyerandrea dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT mullersusanne dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT ottstephan dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT pfisterlisa dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT quitmannjulia dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT romanosmarcel dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT rutschfrank dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT schaubertkristina dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT schubertkatharina dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT schulzjorgb dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT schweigersusann dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT tuscheroliver dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT ungethumkathrin dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT wagnerthomasof dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT haaskirsten dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy
AT dualguidancestructureforevaluationofpatientswithuncleardiagnosisincentersforrarediseaseszseduostudyprotocolforacontrolledmulticentercohortstudy